Profound Medical PROF
5.76
0.16
2.86%
as of 25 Sep
- Market cap
- $204.6M
- P/E
- 0.0×
Follow PROF
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(124.49%) | (67.12%) | (70.59%) | (73.53%) | |
| (93.08%) | (57.64%) | (57.92%) | (58.44%) | ||
ROIC |
(223.73%) | (230.01%) | (174.72%) | (137.78%) | |
Return on Tangible Assets |
(123.24%) | (60.20%) | (65.26%) | (65.09%) | |
Average Days of Receivables |
208.48 | 163.25 | 182.81 | 183.86 | |
Free Cash Flow per Share |
(1.25) | (1.29) | (1.06) | (0.99) | |
Free Cash Flow |
(37.52) | (38.86) | (38.51) | (36.10) | |
Capital Expenditures |
— | (0.65) | — | — | |
Piotroski F-Score |
4.00 | 5.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(61.06%) | (29.24%) | (33.71%) | (38.99%) | |
Accounts Receivable Turnover |
1.88 | 2.26 | 2.45 | 2.63 | |
Accounts Payable Turnover |
1.91 | 3.27 | 3.41 | 5.66 | |
Inventory Turnover |
0.53 | 0.67 | 0.69 | 0.57 | |
Average Days of Payables |
66.54 | 121.25 | 143.67 | 64.73 | |
Days of Inventory on Hand |
773.71 | 639.08 | 603.71 | 708.72 | |
Tax Rate |
0.00 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
146.70% | 127.94% | 111.88% | 107.96% | |
Selling, General and Administrative Expense of Revenue |
221.17% | 199.10% | 161.75% | 149.14% | |
Share Based Compensation of Revenue |
31.83% | 34.10% | 29.49% | 26.05% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.95 | 0.90 | 0.99 | 1.10 | |
Depreciation/Fixed assets |
2.04 | 0.80 | 0.73 | 0.88 | |
Capex/Depreciation |
0.00 | (1.17) | 0.00 | 0.00 | |
Revenue per Share |
0.47 | 0.53 | 0.52 | 0.53 | |
Operating CF per Share |
(1.25) | (1.26) | (1.06) | (0.99) | |
Capex per Share |
0.00 | (0.02) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.04 | 0.00 | 0.00 | |
Net Profit Margin |
(275.18%) | (264.44%) | (206.76%) | (171.56%) |
Columns are period end dates